Table 3.

Odds ratio of CHF based on pre-specified subgroups

Grades	Subgroup	Number of trials	VEGFR-TKIs	Control	I2 (%)	OR (95% CI)	P value	P for group difference
			Events/total, n	Events/total, n
All grade	Overall	12	152/1957	56/1407	0	2.37 (1.76, 3.20)	<0.001	NA
	Tumour types
	RCC	2	83/428	44/378	0	1.91 (1.30, 2.80)	0.001	0.071
	Non-RCC	10	69/1529	12/1029	0	3.36 (2.08, 5.43)	<0.001
	VEGFR-TKIs
	Sunitinib	3	100/690	48/566	26.0	1.95 (1.37, 2.78)	<0.001	0.55
	Sorafenib	1	9/47	1/49	0	6.14 (1.67, 22.59)	0.006
	Axitinib	1	1/314	0/316	0	7.44 (0.15, 374.8)	0.32
	Cediranib	2	19/84	3/49	0	5.37 (2.02, 14.3)	0.001
	Vandetanib	1	1/231	0/100	0	4.19 (0.06, 299.27)	0.51
	Pazopanib	3	21/353	4/210	0	2.40 (1.01, 5.69)	0.047
	Ramucirumab	1	1/238	0/117	0	4.44 (0.07, 287.50)	0.48
	Phase of trials
	Phase II	7	34/665	6/628	0	4.77 (2.41, 9.43)	<0.001	0.026
	Phase III	5	118/1292	50/779	0	2.01 (1.44, 2.81)	<0.001
High grade	Overall	15	28/2577	5/2056	0	3.51 (1.74, 7.05)	<0.001	NA
	Tumour types
	RCC	2	15/428	4/378	0	3.02 (1.21, 7.55)	0.008	0.72
	Non-RCC	13	13/2149	1/1678	0	4.31 (1.46, 12.72)	0.018
	VEGFR-TKIs
	Sunitinib	6	21/1310	5/1192	0	3.19 (1.46, 6.95)	0.004	0.99
	Sorafenib	1	1/47	0/49	0	7.71 (0.15, 388.9)	0.31
	Axitinib	1	1/314	0/316	0	7.44 (0.15, 374.8)	0.32
	Cediranib	2	1/53	0/18	0	3.82 (0.04, 345.5)	0.56
	Vandetanib	1	1/231	0/100	0	4.19 (0.06, 299.3)	0.51
	Pazopanib	3	3/353	0/233	0	4.52 (0.41, 50.16)	0.22
	Ramucirumab	1	0/238	0/117	0	NA	NA
	Phase of trials
	Phase II	7	3/665	1/628	0	2.21 (0.29, 16.72)	0.44	0.67
	Phase III	8	25/1912	4/1428	0	3.73 (1.77, 7.86)	<0.001

RCC, renal cell carcinoma; NA, not available.